Catalytic Differences between Flavohemoglobins of and .

The sole known heme enzyme of the parasitic protist is a flavohemoglobin (gFlHb) that acts as a nitric oxide dioxygenase (NOD) and protects the organism from the free radical nitric oxide. To learn more about the properties of this enzyme, we measured its nitric oxide dioxygenase, NADH oxidase, and cytochrome reductase activities and compared these to the activities of the flavohemoglobin (Hmp). The turnover number for the NOD activity of gFlHb (23 s) is about two-thirds of that of Hmp (34 s) at pH 6.

Practice Patterns of Palmoplantar Pustulosis: Patient Demographics and Treatment Options.

Background: Palmoplantar pustulosis (PPP) is a chronic skin condition characterized by sterile pustules on the palms and soles. This condition is more commonly reported among women and smokers causing considerable discomfort and interference with daily activities. Although there are various off-label treatment options available for PPP, there remains a demand to identify more effective and safer treatments.

Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis.

Atopic dermatitis (AD) is a chronic heterogeneous condition characterized by erythematous, pruritic, and inflamed skin. Janus kinase (JAK) inhibitors are a new class of drugs that target proteins in the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway. These drugs can be administered orally or topically to inhibit signaling of the JAK-STAT pathway and minimize the production of proinflammatory cytokines.

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib.

The Janus kinases (JAK) are a group of molecules, composed of JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), which are key components within the JAK-signal transducers and activators of transcription pathway, where cytokine receptor signaling takes place. These molecules play a foundational role in the underlying pathogenesis of multiple immune-related conditions such as atopic dermatitis (AD), rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and others. Thus far, JAK inhibitors for inflammatory conditions have only been marketed for the treatment of rheumatoid arthritis and psoriatic arthritis, but ongoing phase II and phase III clinical trials for other immune-mediated diseases, such as AD, have also shown promising results.

Abrocitinib for the treatment of atopic dermatitis.

Introduction: Janus kinase (JAK) inhibitors are emerging treatments in dermatology. Also known as JAKinibs, these agents target JAK-signal transducers and activators of transcription (JAK-STAT) pathway for intracellular signaling. Among the various immune-mediated inflammatory skin diseases that the JAK-STAT pathway plays a role in, atopic dermatitis (AD) is an important one.

Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis.

Introduction: Atopic dermatitis (AD) is a common and debilitating dermatosis that often impacts the physical and psychological quality of life in children and adults. A limited number of treatment options are available for AD, and often these treatments result in an insufficient response or may be contraindicated for some patients. This treatment gap creates an increasing demand for alternative AD therapies.